FDA Pharmacy Compounding Advisory Committee (PCAC) — meeting of July 23–24, 2026. Each vote decides whether the committee recommends adding the peptide to the 503A bulk drug substances list (whether compounding pharmacies may make it). A majority Yes = recommended.
Source: on-site vote-board photos · Last updated 24 Jul 2026
Note:These are advisory-committee recommendations, not final FDA rules. The FDA is not required to follow the committee's vote; a substance's actual compounding status is set through later agency rulemaking. Counts and member votes were transcribed from meeting-room photos and may contain minor errors — verify against the official FDA record before publishing.